{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Meagher NS"],"funding":["NSW Ministry of Health","Intramural NIH HHS","Cancer Research UK","NCI NIH HHS"],"pagination":["1834-1846"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8207534"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(12)"],"pubmed_abstract":["Primary ovarian mucinous tumors can be difficult to distinguish from metastatic gastrointestinal neoplasms by histology alone. The expected immunoprofile of a suspected metastatic lower gastrointestinal tumor is CK7<sup>-</sup>/CK20<sup>+</sup>/CDX2<sup>+</sup>/PAX8<sup>-</sup>. This study assesses the addition of a novel marker SATB2, to improve the diagnostic algorithm. A test cohort included 155 ovarian mucinous tumors (105 carcinomas and 50 borderline tumors) and 230 primary lower gastrointestinal neoplasms (123 colorectal adenocarcinomas and 107 appendiceal neoplasms). All cases were assessed for SATB2, PAX8 CK7, CK20, and CDX2 expression on tissue microarrays. Expression was scored in a 3-tier system as absent, focal (1-50% of tumor cells) and diffuse ( >50% of tumor cells) and then "],"journal":["Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc"],"pubmed_title":["A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases."],"pmcid":["PMC8207534"],"funding_grant_id":["16561","10119","22905","P50 CA159981","RG171797","Z99 CA999999","10124","R25 CA092049"],"pubmed_authors":["Shah M","Garcia-Closas M","Kennedy CJ","Kobel M","Daley F","Harnett PR","Etter JL","Lubinski J","Gui X","Pharoah PDP","Wang L","Swerdlow AJ","Wang Q","Winham SJ","Larson MC","Gorringe KL","Menkiszak J","Gronwald J","Natanzon Y","Lambie N","Odunsi K","Bilic S","Stewart C","Alsop J","Gentry-Maharaj A","Zhang B","El-Bahrawy MA","Karpinskyj C","Bathe OF","Schoemaker MJ","Chang-Claude J","Sharma R","Herpel E","Kelemen LE","Klonowski P","Tan A","Rambau PF","Widschwendter M","Modugno F","Carney ME","Keeney GL","Koziak JM","Jimenez-Linan M","Hernandez BY","Kluz T","Kristjansdottir B","Farrell R","Gayther SA","Cook LS","Meagher NS","Vierkant RA","Talhouk A","Tang K","Menon U","deFazio A","Chow C","Mateoiu C","Ramus SJ","Sundfeldt K","Toloczko-Grabarek A","Steed H","Behrens S","Intermaggio MP","Huntsman DG","Cohen P","Coulson P","Moysich KB","Edwards RP","Minoo P","Brenton JD","Goodman MT","Luk H","Jung A","Wilkens LR","Campbell I","Ness RB","Oszurek O","Anglesio MS","Robertson G","Leung Y","Sinn P","Goode EL"],"additional_accession":[]},"is_claimable":false,"name":"A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.","description":"Primary ovarian mucinous tumors can be difficult to distinguish from metastatic gastrointestinal neoplasms by histology alone. The expected immunoprofile of a suspected metastatic lower gastrointestinal tumor is CK7<sup>-</sup>/CK20<sup>+</sup>/CDX2<sup>+</sup>/PAX8<sup>-</sup>. This study assesses the addition of a novel marker SATB2, to improve the diagnostic algorithm. A test cohort included 155 ovarian mucinous tumors (105 carcinomas and 50 borderline tumors) and 230 primary lower gastrointestinal neoplasms (123 colorectal adenocarcinomas and 107 appendiceal neoplasms). All cases were assessed for SATB2, PAX8 CK7, CK20, and CDX2 expression on tissue microarrays. Expression was scored in a 3-tier system as absent, focal (1-50% of tumor cells) and diffuse ( >50% of tumor cells) and then ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Dec","modification":"2025-04-04T11:48:04.743Z","creation":"2022-02-10T14:45:25.461Z"},"accession":"S-EPMC8207534","cross_references":{"pubmed":["31239549"],"doi":["10.1038/s41379-019-0302-0"]}}